324 related articles for article (PubMed ID: 25239274)
1. Current concepts on the molecular pathology of non-small cell lung carcinoma.
Fujimoto J; Wistuba II
Semin Diagn Pathol; 2014 Jul; 31(4):306-13. PubMed ID: 25239274
[TBL] [Abstract][Full Text] [Related]
2. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
3. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.
Rekhtman N; Brandt SM; Sigel CS; Friedlander MA; Riely GJ; Travis WD; Zakowski MF; Moreira AL
J Thorac Oncol; 2011 Mar; 6(3):451-8. PubMed ID: 21266922
[TBL] [Abstract][Full Text] [Related]
4. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA
Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171
[TBL] [Abstract][Full Text] [Related]
5. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
6. Pathology of non-small cell lung cancer. New diagnostic approaches.
Linnoila I
Hematol Oncol Clin North Am; 1990 Dec; 4(6):1027-51. PubMed ID: 1962774
[TBL] [Abstract][Full Text] [Related]
7. Adequacy of endobronchial ultrasound transbronchial needle aspiration samples in the subtyping of non-small cell lung cancer.
Esterbrook G; Anathhanam S; Plant PK
Lung Cancer; 2013 Apr; 80(1):30-4. PubMed ID: 23312886
[TBL] [Abstract][Full Text] [Related]
8. Genes and pathology of non-small cell lung carcinoma.
Sakashita S; Sakashita M; Sound Tsao M
Semin Oncol; 2014 Feb; 41(1):28-39. PubMed ID: 24565579
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
[TBL] [Abstract][Full Text] [Related]
12. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing.
Moreira AL; Thornton RH
Clin Lung Cancer; 2012 Sep; 13(5):334-9. PubMed ID: 22424871
[TBL] [Abstract][Full Text] [Related]
14. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
15. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
Vavalà T; Monica V; Lo Iacono M; Mele T; Busso S; Righi L; Papotti M; Scagliotti GV; Novello S
Lung Cancer; 2017 May; 107():84-90. PubMed ID: 27346245
[TBL] [Abstract][Full Text] [Related]
16. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.
Vanderlaan PA; Yamaguchi N; Folch E; Boucher DH; Kent MS; Gangadharan SP; Majid A; Goldstein MA; Huberman MS; Kocher ON; Costa DB
Lung Cancer; 2014 Apr; 84(1):39-44. PubMed ID: 24513263
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
18. Pitfalls in lung cancer molecular pathology: how to limit them in routine practice?
Ilie M; Hofman P
Curr Med Chem; 2012; 19(16):2638-51. PubMed ID: 22506768
[TBL] [Abstract][Full Text] [Related]
19. Personalized medicine for lung cancer: new challenges for pathology.
Kerr KM
Histopathology; 2012 Mar; 60(4):531-46. PubMed ID: 21916947
[TBL] [Abstract][Full Text] [Related]
20. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Canberk S; Engels M
Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
